Login to Your Account



Clinic Roundup


Thursday, July 19, 2012
• Angion Biomedica Corp., of Uniondale, N.Y., said the first patient was dosed in a Phase II trial testing BB3, a small-molecule mimetic of hepatocyte growth factor, for the treatment of heart attack.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription